title: Risk factors for postherpetic neuralgia.
abstract: BACKGROUND
  The risk factors for postherpetic neuralgia (PHN), the most common complication of herpes zoster, have not been well established.
  
  
  OBJECTIVE
  To elucidate the risk factors for PHN.
  
  
  METHODS
  Automated medical, claims, and pharmacy records of a health maintenance organization were used to identify cases of PHN and obtain data on risk factors. A case-base design was used to assess the impact of various patient, disease, and treatment factors on the prevalence of PHN 1 and 2 months after developing zoster.
  
  
  RESULTS
  There were 821 cases of herpes zoster that met all eligibility criteria. The prevalence of PHN more than 30 days after onset of zoster was 8.0% (95% confidence interval [CI], 6.3%-10.1%) and 4.5% (95% CI, 3.2%-6.2%) after 60 days. Compared with patients younger than 50 years, individuals aged 50 years or older had a 14.7-fold higher prevalence (95% CI, 6.8-32.0) 30 days and a 27.4-fold higher prevalence (95% CI, 8.8-85.4) 60 days after developing zoster. Prodromal sensory symptoms and certain conditions associated with compromised immunity were also associated with PHN. Systemic corticosteroids before zoster and treatment of zoster with acyclovir or corticosteroids did not significantly affect the prevalence of PHN.
  
  
  CONCLUSIONS
  Increased age and prodromal symptoms are associated with higher prevalence of PHN 1 and 2 months after onset of zoster. Overall, systemic acyclovir appears not to confer any protection against PHN, although benefit among elderly patients cannot be excluded.
authors.affiliation: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA.
authors.forename: P W
authors.initials: PW
authors.lastname: Choo
authors.forename: K
authors.initials: K
authors.lastname: Galil
authors.forename: J G
authors.initials: JG
authors.lastname: Donahue
authors.forename: A M
authors.initials: AM
authors.lastname: Walker
authors.forename: D
authors.initials: D
authors.lastname: Spiegelman
authors.forename: R
authors.initials: R
authors.lastname: Platt
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D015897:Comorbidity; D005260:Female; D006279:Health Maintenance Organizations; D006562:Herpes Zoster / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000453:epidemiology / Q000821:virology*; D015995:Prevalence; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir